Aytu BioScience

Maxim Group's Naz Rahman maintains Buy rating on Neurosense Therapeutics Ltd. (NRSN), with shares closing at $1.13. Rahman has an average return of -13.1% and a 27.82% success rate. The analyst consensus on NRSN is a Moderate Buy with an average price target of $3.00. NRSN has a one-year high of $2.33 and a low of $0.40, with an average volume of 306.5K. Neurosense Therapeutics focuses on developing treatments for neurodegenerative diseases, with its lead candidate being PrimeC.